Scarica l'app Stockscreener
13.62
7.03%
-1.03
Dopo l'orario di chiusura:
13.62
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ERAS Giù?
Forum
Previsione
Erasca Inc Borsa (ERAS) Ultime notizie
Assessing Tango Therapeutics (TNGX) Valuation After Vopimetostat Progress And New Erasca Collaboration - simplywall.st
Erasca secures worldwide rights to RAS-targeting drug ERAS-0015 By Investing.com - Investing.com Nigeria
Erasca’s Chief Medical Officer Divests Shares Amid Strategic Uncertainties - StocksToTrade
Erasca stock price target raised to $20 by H.C. Wainwright on trial data - Investing.com Nigeria
Stifel reiterates Buy rating on Erasca stock, $20 target - Investing.com
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Decoding Erasca Inc (ERAS): A Strategic SWOT Insight - GuruFocus
Erasca, Inc. 2025 Annual Report: Erasing Cancer with Modality-Agnostic RAS/MAPK Pathway Therapeutics and Innovative Precision Oncology Strategies - Minichart
Erasca 10-K: Net loss $124.55M; cash and securities $341.8M - TradingView
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results - Bitget
A Look At Erasca (ERAS) Valuation After Securing Global Rights To ERAS-0015 - simplywall.st
Erasca (ERAS) to Release Earnings on Thursday - MarketBeat
Stifel raises Erasca stock price target to $20 on China expansion - Investing.com
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau - Bitget
Global cancer drug rights: Erasca takes ERAS-0015 worldwide - Stock Titan
Erasca Inc stock hits 52-week high at $14.63 - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Hits New 52-Week HighTime to Buy? - MarketBeat
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts - 24/7 Wall St.
Erasca (ERAS) And Tango Target MTAP-Deleted Cancers With Dual Inhibition Strategy – What Changes? - simplywall.st
Growth Recap: How interest rate cuts could boost Erasca Inc. stock2025 Technical Overview & Community Verified Watchlist Alerts - Naître et grandir
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS - The Globe and Mail
Tango Therapeutics Stock Jumps 36% to a New High. Here’s What’s Driving the Move - TIKR.com
Erasca Insider Sold Shares Worth $300,760, According to a Recent SEC Filing - marketscreener.com
Erasca’s chief medical officer Morris sells $300k in ERAS stock - Investing.com
Erasca (ERAS) Sees Target Price Raised By Clear Street To $20 | - GuruFocus
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - Sahm
Tango Therapeutics rallies after oncology drug collaboration with Erasca - Mugglehead Investment Magazine
Clear Street raises Erasca stock price target on combination trial deal - Investing.com Australia
Clear Street raises Erasca stock price target on combination trial deal By Investing.com - Investing.com South Africa
Erasca and Tango Therapeutics Partner to Study ERAS-007 and Vopimetostat Combination for MTAP-Deleted Cancers - geneonline.com
Assessing Tango Therapeutics (TNGX) Valuation After Earnings Update And New Erasca Trial Collaboration - simplywall.st
Tango rises after Q4 results, clinical pact with Erasca - Seeking Alpha
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat - Bitget
Biopharmaceutical company Erasca, Inc. (NASDAQ: ERAS) and Tango Therapeutics Inc. (NASDAQ: TNGX) announced a clinical collaboration to jointly conduct clinical evaluation of the combination therapy of ERAS-0015 and vopimetostat. - Bitget
Erasca, Tango Therapeutics Partner on Phase 1/2 Trial for Combination Cancer Therapy - marketscreener.com
Erasca and Tango Therapeutics enter into clinical collaboration to evaluate combination of ERAS-0015 and vopimetostat - marketscreener.com
Erasca, Tango test dual-drug attack on tough pancreatic, lung cancers - Stock Titan
Erasca Inc stock hits 52-week high at $14.63 By Investing.com - Investing.com Canada
Erasca stock reaches 52-week high at 12.48 USD - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Hits New 1-Year HighShould You Buy? - MarketBeat
Assessing Erasca (ERAS) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Erasca, Inc. (ERAS): A Bull Case Theory - Insider Monkey
Erasca Conference: ERAS Teases 2026 Catalysts for Pan-RAS ERAS-0015 and Pan-KRAS ERAS-4001 - Yahoo Finance
ERAS: Lead RAS-targeted therapies show strong early data, with major trial updates expected in 2024 - TradingView
ERAS: Lead RAS-targeted therapies show promising early results, with key clinical updates expected in 2024 - TradingView
Erasca, Inc. (ERAS) Stock Analysis: Unlocking Potential in Precision Oncology with a Robust Pipeline - DirectorsTalk Interviews
Erasca Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Erasca stock hits 52-week high at $13.30 By Investing.com - Investing.com India
Assessing Erasca (ERAS) Valuation After New Pan KRAS Patent Win Through 2043 - simplywall.st
Erasca (NASDAQ:ERAS) Hits New 12-Month HighHere's What Happened - MarketBeat
Erasca stock hits 52-week high at $13.30 - Investing.com
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):